| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
3-Methylcytidine is a modified nucleoside that is incorporated into RNA. Its presence and levels can reflect RNA modification patterns and cellular metabolism. As a urinary nucleoside, its levels in urine can serve as a biomarker for cancer. Elevated levels of modified nucleosides in urine are associated with increased cell turnover and RNA metabolism in tumors.
|
|---|---|
| ln Vitro |
In vitro, 3-Methylcytidine is used as a standard for the detection and quantification of modified nucleosides. It is used in studies of RNA modifications and their effects on gene expression. Its levels in biological samples can be measured by LC-MS or other analytical techniques.
|
| ln Vivo |
In vivo, 3-Methylcytidine is a normal metabolite found in urine. Its levels can be elevated in patients with certain types of cancer, making it a potential biomarker for early detection and monitoring of disease. Its role as a biomarker is an active area of research.
|
| Enzyme Assay |
For metabolite quantification, 3-Methylcytidine is measured in urine or other biological samples using LC-MS or GC-MS. Samples are processed, and the compound is separated on a suitable column and detected by mass spectrometry. Quantification is performed using external calibration curves or isotope-labeled internal standards.
|
| Cell Assay |
For cellular studies, cells are cultured, and the levels of 3-methylcytidine in the culture medium or cell lysates are measured. Cells may be treated with compounds that affect RNA methylation, and the resulting changes in 3-methylcytidine levels are measured.
|
| Animal Protocol |
For in vivo studies, urine samples are collected from animal models or human subjects. 3-Methylcytidine levels are measured by LC-MS. Its levels are correlated with disease status (e.g., tumor burden) to assess its potential as a biomarker.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3-Methylcytidine are not applicable, as it is an endogenous metabolite. Its levels in urine reflect its production and clearance rates. It is excreted in urine. No specific PK parameters are reported.
|
| Toxicity/Toxicokinetics |
3-Methylcytidine is a normal metabolite and is not considered toxic at physiological concentrations. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As a research chemical, it should be handled according to standard laboratory safety protocols.
|
| References | |
| Additional Infomation |
3-Methylcytidine is a type of methylcytidine. It has been reported that 3-methylcytidine has been found in Geodia barretti, and relevant data are available for reference.
3-Methylcytidine (CAS 2140-64-9) is a modified nucleoside and a urinary biomarker for lung, gastric, colon, and breast cancer. It has the molecular formula C₁₀H₁₅N₃O₅ and a molecular weight of 257.24. It is used in studies of RNA modifications and cancer biomarkers and is strictly for research use. |
| Molecular Formula |
C10H15N3O5
|
|---|---|
| Molecular Weight |
257.2432
|
| Exact Mass |
257.101
|
| CAS # |
2140-64-9
|
| PubChem CID |
14237477
|
| Appearance |
White to off-white solid powder
|
| Density |
1.71g/cm3
|
| Boiling Point |
471.9ºC at 760mmHg
|
| Flash Point |
239.2ºC
|
| Vapour Pressure |
6.88E-11mmHg at 25°C
|
| Index of Refraction |
1.701
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
399
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN1C(=N)C=CN(C1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
RDPUKVRQKWBSPK-ZOQUXTDFSA-N
|
| InChi Code |
InChI=1S/C10H15N3O5/c1-12-6(11)2-3-13(10(12)17)9-8(16)7(15)5(4-14)18-9/h2-3,5,7-9,11,14-16H,4H2,1H3/t5-,7-,8-,9-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-imino-3-methylpyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~90 mg/mL (~349.87 mM)
DMSO : ~83.33 mg/mL (~323.94 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (388.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8874 mL | 19.4371 mL | 38.8742 mL | |
| 5 mM | 0.7775 mL | 3.8874 mL | 7.7748 mL | |
| 10 mM | 0.3887 mL | 1.9437 mL | 3.8874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
